PDCD1 and non-small cell lung carcinoma: Integrating anti-PD1/PD-L1 and SBRT notably improved survival in early-stage NSCLC patients154 but yielded disparate results in metastatic NSCLC, underscoring the impact of tumour volume and prior therapies in SBRT and ICI utilization.